367500-94-5

Basic information

• Product Name: 2-Carboxy-6-fluoroimidazo[1,2-a]pyridine
• Synonyms: 2-Carboxy-6-fluoroimidazo[1,2-a]pyridine;IMidazo[1,2-a]pyridine-2-carboxylic acid, 6-fluoro-
• CAS NO: 367500-94-5
• Molecular Formula: C₈H₅FN₂O₂
• Molecular Weight: 180.1359032
• Mol File: 367500-94-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Carboxy-6-fluoroimidazo[1,2-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Carboxy-6-fluoroimidazo[1,2-a]pyridine(367500-94-5)
• EPA Substance Registry System: 2-Carboxy-6-fluoroimidazo[1,2-a]pyridine(367500-94-5)

Safety Data

• Hazardous Substances Data: 367500-94-5(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
2-Carboxy-6-fluoroimidazo[1,2-a]pyridine is used as a research compound for its unique structural features, including the presence of a fluorine atom and a carboxy group. These functional groups make it a valuable candidate for various chemical studies and potential applications in the development of new materials or pharmaceuticals.
Used in Pharmaceutical Development:
2-Carboxy-6-fluoroimidazo[1,2-a]pyridine is used as a starting material or intermediate in the synthesis of pharmaceutical compounds. Its imidazole ring and fluorine substitution can contribute to the development of new drugs with improved properties, such as increased stability, bioavailability, or target specificity.
Used in Material Science:
2-Carboxy-6-fluoroimidazo[1,2-a]pyridine is used as a building block in the creation of new materials with specific properties. The combination of the imidazole ring and the fluorine atom can lead to the development of materials with unique electronic, optical, or mechanical characteristics, which can be applied in various industries, such as electronics, energy, or aerospace.

Upstream product

• 1341231-96-6 methyl 5-chloro-6-cyano-2-(3-fluorophenyl)nicotinate 
• 1341232-04-9 methyl 6-[(acetylamino)methyl]-5-chloro-2-(3-fluorophenyl)nicotinate 
• 1341232-15-2 methyl 2,5-dichloro-6-cyanonicotinate 
• 1341232-14-1 2,5-dichloro-3-(methoxycarbonyl)pyridine 1-oxide 
• 67754-03-4 methyl 2,5-dichloronicotinate 
• 59782-85-3 2,5-dichloronicotinic acid 
• 21717-96-4 2-amino-5-fluoropyridine 
• 367500-93-4 6-fluoro-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester 

Downstream Products

• 1038827-63-2 (6-fluoroimidazo[1,2-a]pyridin-2-yl)methanol 
• 1197289-06-7 N-((1s,4s)-4-(2-(2'-((1,4-oxazepan-4-yl)methyl)-4'-hydroxybiphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexyl)-6-fluoroimidazo[1,2-a]pyridine-2-carboxamide trifluoroacetic acid salt 
• 1610736-84-9 N-((1s,4s)-4-(2-(2'-((dimethylamino)methyl)-4'-hydroxybiphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexyl)-6-fluoroimidazo[1,2-a]pyridine-2-carboxamide trifluoroacetic acid salt 
• 1610737-07-9 N-((1s,4s)-4-(2-(4'-(((3S,5R)-3,5-dimethylpiperazin-1-yl)methyl)biphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexyl)-6-fluoroimidazo[1,2-a]pyridine-2-carboxamide trifluoroacetic acid salt 
• 583881-21-4 C₂₂H₂₃Cl₂FN₄O₃ 

Relevant articles and documents

Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents

A series of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides (IPAs), based on the structure of WZY02 discovered in our lab, were designed and synthesized as new anti-TB agents. Results reveal that many of them exhibit excellent in vitro inhibitory activity with low nanomolar MIC values against both drug-sensitive MTB strain H37Rv and drug-resistant clinical isolates. Compounds 15b and 15d display good safety and pharmacokinetic profiles, suggesting their promising potential to be lead compounds for future antitubercular drug discovery.

HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Synthesis and biological activities of indolizine derivatives as alpha-7 nAChR agonists

Human α7 nicotinic acetylcholine receptor (nAChR) is a promising therapeutic target for the treatment of schizophrenia accompanied with cognitive impairment. Herein, we report the synthesis and agonistic activities of a series of indolizine derivatives targeting to α7 nAChR. The results show that all synthesized compounds have affinity to α7 nAChR and some give strong agonistic activity, particularly most active agonists show higher potency than control EVP-6124. The docking and structure-activity relationship studies provide insights to develop more potent novel α7 nAChR agonists.

FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES

A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[l,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

Chemical compounds

The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.